Cancer and COVID-19, a dangerous association
Keywords:
Coronavirus infections, SARS virus, coronavirus disease 2019, SARS-CoV-2, Covid-19, cancer, malignant neoplasmAbstract
Background:COVID-19 is a pandemic caused by the SARS-CoV-2 virus which relation with cancer may have adverse effects.
Objective:To describe the main associations between cancer and COVID-19.
Methodology:A literature review was conducted in Google Scholar, SciELO and PubMed Central with the descriptors SARS-CoV-2, COVID-19 and cancer, consulted in DeCS. Full-text articles in Spanish and English were selected, mainly from peer-reviewed journals.
Results:COVID-19 produces more non-favorable outcomes in patients with cancer. These outcomes are related to high hospitalization rates, complications and mortality. Frequent comorbidity relations in patients with cancer seem to contribute to this dangerous association. Signaling pathways common to cancer and SARS-CoV-2 infection are proinflammatory cytokines, type I interferon, androgen receptor, and immune checkpoints. This knowledge has a practical use with drugs against COVID-19 in patients with cancer.
Conclusions:Cancer is associated with severe COVID-19, making such patients more vulnerable to viral infection.
Downloads
References
1. Nolen SC, Evans MA, Fischer A, Corrada MM, Kawas CH, Bota DA. Cancer-Incidence, prevalence and mortality in the oldest-old. A comprehensive review. Mech Ageing Dev [Internet]. 2017 [cited 2022 Jan 15]; 164:113-126. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788911/pdf/nihms887025.pdf
2. Rubio MC, Sanchez L, Abreu-Ruíz G, Bermejo-Bencomo W, Crombet T, Lage A. COVID-19 and Cancer in Cuba. Seminars in Oncology [Internet]. 2020 [ cited 2022 Jan 15]47(5):328-329. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0093775420300865
3. Garrido-Tapia E, Manso-López A, Salermo-Reyes M, Ramírez-Ramírez G, Pérez-Rodríguez V. Características clínico-epidemiológicas y algunas reflexiones sobre la COVID-19 en Holguín, Cuba, 2020. CCM [Internet]. 2020 [citado 20 Abr 2022];24(3):839-55. Disponible en: https://www.medigraphic.com/pdfs/correo/ccm-2020/ccm203b.pdf
4 Hwang JK, Zhang T, Wang AZ, Li Z. COVID-19 vaccines for patients with cancer: benefits likely outweigh risks. J Hematol Oncol [Internet]. 2021 [cited 2022 Apr 20];14(1):38 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910769/pdf/13045_2021_Article_1046.pdf
5. Castañeda CA, Castillo M, Rojas JL, Fuentes H, Gómez HL. COVID-19 en pacientes con cáncer: revisión sistemática. Rev Peru Med Exp Salud Publica [Internet]. 2020 [citado 20 Abr 2022]; 37(4):611-619. Disponible en: https://scielosp.org/article/rpmesp/2020.v37n4/611-619/es/
6. Serra Valdés MÁ. Las enfermedades crónicas no transmisibles y la pandemia por COVID-19. Finlay [Internet]. 2020 [citado 20 Abr 2022];10(2):78-8. Disponible en: https://www.medigraphic.com/pdfs/finlay/fi-2020/fi202c.pdf
7. Petrova D, Pérez-Gómez B, Pollán M, Sánchez MJ. Implicaciones de la pandemia por COVID-19 sobre el cáncer en España. Med Clin (Barc) [Internet].2020 [citado 20 Abr 2022];155(6):263-266. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205671/pdf/main.pdf
8. Seneviratne SL, Wijerathne W, Yasawardene P, Somawardana B. COVID-19 in cancer patients, Trans R Soc Trop Med Hyg. [Internet]. 2022 [cited 2022 Apr 20];0:1-31. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992310/pdf/trac015.pdf
9. Van Dam PA, Huizing M, Mestach G, Dierckxsens S, Tjalma W, Trinh XB, et al. SARS-CoV-2 and cancer: Are they really partners in crime? Cancer Treat Rev.[Internet] 2020 [cited 2022 Jan 15];89. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351667/pdf/main.pdf
10. Shumilov E, Hoffknecht P, Koch R, Peceny R, Voigt S, Schmidt N, et al. Diagnostic, Clinical and Post-SARS-CoV-2 Scenarios in Cancer Patients with SARS-CoV-2: Retrospective Analysis in Three German Cancer Centers. Cancers [Internet]. 2021 [cited 2022 Jan 15];13 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230714/pdf/cancers-13-02917.pdf
11. Dovey Z, Mohamed N, Gharib Y, Ratnani P, Hammouda N, Nair SS, et al. Impact of COVID-19 on Prostate Cancer Management: Guidelines for Urologists. Eur Urol Open Sci [Internet]. 2020 [cited 2022 Jan 15];20:1-11. Available from: https://www.sciencedirect.com/science/article/pii/S2666168320351120
12. Berzenji L, Vercauteren L, Yogeswaran SK, Lauwers P, Hendriks JM, Van Schil PE. Safety and Feasibility of Lung Cancer Surgery under the COVID-19 Circumstance. Cancers. 2022; 14: 1334. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7296308/pdf/main.pdf
13. Zong Z, Wei Y, Ren J, Zhang L, Zhou F. The intersection of COVID-19 and cancer: signaling pathways and treatment implications. Molecular Cancer [Internet]. 2021 [cited 2022 Jan15];20. Available from: https://molecular-cancer.biomedcentral.com/track/pdf/10.1186/s12943-021-01363-1.pdf
14. Ye C, Qi L, Wang J, Zheng S. COVID-19 Pandemic: Advances in Diagnosis, Treatment, Organoid Applications and Impacts on Cancer Patient Management. Front Med.[Internet] 2021 [cited 2022 Jan 15];8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039300/pdf/fmed-08-606755.pdf
15. Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, et al. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol [Internet] 2021 [cited 2022 Apr 20];18(5):313-319. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957448/pdf/41571_2021_Article_487.pdf
16. Schmidt AL, Labaki C, Hsu CY, Bakouny Z, Balanchivadze N, Berg SA, et al. COVID-19 vaccination and breakthrough infections in patients with cancer. Ann Oncol [Internet]. 2022 [cited 2022 Apr 20];33(3):340-346 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704021/pdf/main.pdf
17. Heudel P, Favier B, Solodky ML, Assaad S, Chaumard N, Tredan O, et al. Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients. Eur J Cancer [Internet]. 2022 [cited 2022 Apr 20];17 Available from: https://reader.elsevier.com/reader/sd/pii/S0959804922000685?token=3DAE247C139184CE04F077F175E7F7D27EC7222D317D1DC99A8CE7DB5FEEAB7522C0F7E4D186F8D9C9D1B99F928518A5&originRegion=eu-west-1&originCreation=20220613163009ç
18. Pathania AS, Prathipati P, Abdul BAA, Chava S, Katta SS, Gupta SC, et al. COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. Theranostics [Internet]. 2021 [cited 2022 Jan 15];11 (2):731-753. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738845/pdf/thnov11p0731.pdf
19. Díaz-Armas M, Sánchez-Artigas R, Matute-Crespo T, Llumiquinga-Achi R. Proteína de la espícula del virus SARS-CoV-2 y su relación con la enzima convertidora de angiotensina-2. Rev Inf Científ [Internet]. 2021 [citado 14 Abr 2022];100(5) Disponible en: http://www.revinfcientifica.sld.cu/index.php/ric/article/view/3633/4918
20. Expósito-Lara A, Feria-Díaz G, González-Benítez S, Miguel-Soca P. Variantes genéticas del SARS-CoV-2 y sus implicaciones clínicas. Medisan [Internet]. 2021 [citado 14 Abr 2022];25(6):[aprox.22p.]. Disponible en: http://www.medisan.sld.cu/index.php/san/article/view/3878
21. Han HJ, Nwagwu C, Anyim O, Ekweremadu C, Kim S. COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology. Int Immunopharmaco [Internet]. 2021 [2022 Jan 15];90. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709613/pdf/main.pdf
22. Luo J, Rizvi, Preeshagul IR, Egger JV, Hoyos D, Bandlamudi C, et al. COVID-19 in patients with lung cancer. Ann Oncol [Internet]. 2020 [cited 2022 Jan 15];31(10):1386-1396. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297689/pdf/main.pdf
23. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol [Internet]. 2020 [cited 2022 Jan 15];31(7):894-901. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270947/pdf/main.pdf
24. Amador M, Matias-Guiu X, Sancho-Pardo G, Contreras Martinez J, de la Torre-Montero JC, Peñuelas Saiz A, et al. Impact of the COVID-19 pandemic on the care of cancer patients in Spain. ESMO Open [Internet]. 2021 [cited 2022 Jan 15];6(3). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128716/pdf/main.pdf
25. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov [Internet]. 2020 [cited 2022 Jan Jun;10(6):783-791. Cancer Discov [Internet]. 2020 [cited 2022 Jan 15];10(6):783-791. Availalable from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309152/pdf/candisc-10-783.pdf
26. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet [Internet]. 2020 [cited 2022. Jan 15];395(10241):1907-1918. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255743/pdf/main.pdf
27. Lee LYW, Cazier JB, Angelis V, Arnold R, Bisht V, Campton NA, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. [Internet] 2020 [cited 2022 Jan 15];395(10241):1919-1926. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7255715/pdf/main.pdf
28. Lara Álvarez MÁ, Rogado Revuelta J, Obispo Portero B, Pangua Méndez C, Serrano Montero G, López Alfonso A. Mortalidad porCOVID-19 en pacientes con cáncer en un hospital de Madrid durante las primeras 3 semanas de epidemia. Med Clin (Barc). [Internet]. 2020 [citado 15 Ene 2022];155(5):202-204. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236720/pdf/main.pdf
29. Zhang H, Wang L, Chen Y, Wu Q, Chen G, Shen X, et al. Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan, China. Cancer [Internet]. 2020 [cited 2022 Jan 15];126(17):4023-4031 Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361610/pdf/CNCR-9999-na.pdf
30. Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan RS, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol [Internet]. 2020 [cited 2022 Jan 15];21(8):1023-1034. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417808/pdf/main.pdf
31. Korkusuz R, Sahingoz Erdal G, Kibar Akilli I, Bilge M, Tural D, Kart Yasar K.
Changing characteristics of cancer patients during the COVID-19 pandemic. J Infect Dev Ctries [Internet]. 2022 [cited 2022 Apr 20]31;16(3):453-461. Available from: https://jidc.org/index.php/journal/article/view/35404850/2772
32. Guarneri V, Bassan F, Zagonel V, Milella M, Zaninelli M, Cattelan AM, et al. Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study. Eur J Cancer [Internet] 2021 [cited 2022 Jan 15];147:120-127. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857033/pdf/main.pdf
33. Mousavi SA, Rostami T, Kiumarsi A, Rad S, Rostami M, Motamedi F, et al. COVID-19 and cancer: A comparative case series. Cancer Treat Res Commun [Internet]. 2021 [cited 2022 Jan 15];27. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885684/pdf/main.pdf
34. Trifanescu OG, Gales L, Bacinschi X, Serbanescu L, Georgescu M, Sandu A, et al. Impact of the COVID-19 Pandemic on Treatment and Oncologic Outcomes for Cancer Patients in Romania. In Vivo [Internet]. 2022 [cited 2022 Apr 20];36(2):934-941.Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931923/pdf/in_vivo-36-934.pdf
35. Kathuria-Prakash N, Mosaferi T, Xie M, Antrim L, Angell TE, Gino K, et al. COVID-19 Outcomes of Patients With Differentiated Thyroid Cancer: A Multicenter Los Angeles Cohort Study. Endocr Pract [Internet]. 2021 [cited 2022 Jan 15];27(2):90-94. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831810/pdf/main.pdf
36. Trapani D, Marra A, Curigliano G. The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region. Eur J Cancer [Internet]. 2020 [cited 2022 Jan 15];132:199-206. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188643/pdf/main.pdf
37. Seneviratne SL, Wijerathne W, Yasawardene P, Somawardana B. COVID-19 in cancer patients. Trans R Soc Trop Med Hyg [Internet]. 2022 [cited 2022 Apr 20];0:1-31. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992310/pdf/trac015.pdf
38. Busetto GM, Porreca A, Giudice FD, Maggi M, D'Agostino D, Romagnoli D, et al. SARS-CoV-2 infection and high-risk non-muscle-invasive bladder cancer: are there any common features Urol Int [Internet]. 2020 [cited 2022 Jan 15];1-13. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316644/pdf/uin-0001.pdf
39. Garassino MC, Ribas A. At the Crossroads: COVID-19 and Immune-Checkpoint Blockade for Cancer. Cancer Immunol Res [Internet]. 2021 [cited 2022 Jan 15];9(3):261-264. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052929/pdf/nihms-1691479.pdf
40. Rogiers A, Pires da Silva I, Tentori C, Tondini CA, Grimes JM, Trager MH, et al. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. J Immunother Cancer [Internet] 2021 [cited 2022 Jan 15];9(1). Available rom: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817383/pdf/jitc-2020-001931.pdf
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Yarimi Rodríguez Moldón, María Teresa Díaz Armas, Raisa Rodríguez Duque
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
La revista GME tiene Acceso Abierto (Open Access) a su contenido bajo las premisas de que el libre acceso mejora el sistema de comunicación científica, lo cual elimina cualquier barrera que impida el acceso a la información y de que el mismo autor es el máximo beneficiario de este movimiento, al proporcionarle ventajas tanto en su aspecto económico, científico, como en servicios de valor añadido.
Los autores conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra; podrán establecer acuerdos adicionales para la distribución no exclusiva de la versión de la obra publicada en la revista, con el reconocimiento de haber sido publicado primero en esta revista.
Todo el contenido de esta revista se encuentra en Acceso Abierto, distribuido según los términos de la licencia Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) que permite el uso, distribución y reproducción no comerciales y sin restricciones en cualquier medio, siempre que sea debidamente citada la fuente primaria de publicación.
Download here;
